Neurogenesis, Inc. (NEUN) Stock Analysis

Neurogenesis, Inc. (NEUN) Healthcare & Pipeline Overview

Neurogenesis, Inc., established in 1984, manufactures and distributes nutritional supplements in the U.S., including NeuBecalm'd and NeuRecover, targeting stress reduction and neurotransmitter support. The company also has a research collaboration with the University of Edinburgh for gene therapy development, positioning them within the specialty and generic drug manufacturing sector.

What Is the Investment Thesis for NEUN?

Neurogenesis, Inc. operates in the niche market of nutritional supplements targeting brain health and stress reduction. With a gross margin of 79.6%, the company demonstrates strong pricing power and efficient production. However, the company's negative profit margin of -0.9% indicates challenges in achieving overall profitability. A key growth catalyst is the ongoing research collaboration with the University of Edinburgh, which could lead to breakthroughs in gene therapies and expand the company's product offerings. Investors should monitor the company's ability to translate its high gross margin into net profitability and the progress of its research initiatives. The company's beta of -24.99 suggests an inverse correlation with the market, but this extreme value warrants further investigation to ensure accuracy.

Based on FMP financials and quantitative analysis

NEUN Key Highlights

Gross Margin of 79.6% indicates strong pricing power in the nutritional supplements market.

• Negative Profit Margin of -0.9% suggests challenges in achieving overall profitability despite high gross margins.
• Research collaboration with the University of Edinburgh could lead to expansion into gene therapies.
• Product line includes specialized supplements like NeuBecalm'd and NeuRecover, targeting specific needs such as stress reduction and neurotransmitter replenishment.
• Beta of -24.99 indicates an inverse correlation with the market, but this extreme value warrants further investigation.

Who Are NEUN's Competitors?

NEUN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NEUN's Key Strengths?

Specialized product line targeting specific brain health needs.

• High gross margin.
• Research collaboration with the University of Edinburgh.
• Established brand in its niche.

What Are NEUN's Weaknesses?

Negative profit margin.

• Limited geographic reach (primarily U.S.).
• Small market capitalization.
• Dependence on a limited number of products.

What Could Drive NEUN Stock Higher?

Research collaboration with the University of Edinburgh potentially leading to breakthroughs in gene therapies.

• Potential for new product launches targeting specific neurological conditions.
• Expansion into new geographic markets.

What Are the Key Risks for NEUN?

Negative return on equity (-12.0%) — the business is not currently generating profit on shareholder capital.

• Intense competition in the nutritional supplement industry could erode market share.
• Evolving regulatory landscape for dietary supplements could increase compliance costs.
• Adverse effects from supplements could lead to product liability claims.
• Negative profit margin indicates challenges in achieving overall profitability.

What Are the Growth Opportunities for NEUN?

• Expansion of Product Line: Neurogenesis has the opportunity to expand its product line to address a wider range of neurological and psychological conditions. The market for brain health supplements is projected to reach $13.3 billion by 2028, growing at a CAGR of 8.2%. By developing new formulations and targeting specific conditions such as anxiety, depression, and cognitive decline, Neurogenesis can capture a larger share of this growing market. This expansion could be achieved through internal research and development or through strategic acquisitions of complementary product lines.
• Geographic Expansion: Currently focused on the U.S. market, Neurogenesis can pursue geographic expansion to international markets. The global market for nutritional supplements is estimated at $163.9 billion in 2024 and is expected to reach $230.7 billion by 2029. By entering markets in Europe, Asia, and Latin America, Neurogenesis can diversify its revenue streams and reduce its reliance on the U.S. market. This expansion would require adapting its products to meet local regulations and consumer preferences, as well as establishing distribution networks in new regions.
• Strategic Partnerships: Neurogenesis can form strategic partnerships with healthcare providers, pharmacies, and wellness centers to increase the distribution and visibility of its products. By partnering with these entities, Neurogenesis can reach a wider audience and build brand awareness. These partnerships could involve co-marketing agreements, joint product development, or the integration of Neurogenesis's products into existing healthcare programs. The timeline for establishing these partnerships would depend on the specific agreements and the regulatory requirements in each region.
• E-commerce and Direct-to-Consumer Sales: Neurogenesis can invest in its e-commerce platform and direct-to-consumer sales channels to increase its reach and reduce its reliance on traditional retail channels. The online market for nutritional supplements is growing rapidly, driven by increasing consumer adoption of e-commerce and the convenience of online shopping. By enhancing its website, improving its online marketing efforts, and offering subscription services, Neurogenesis can attract new customers and increase customer loyalty. This initiative could be implemented within the next year.
• Gene Therapy Development: The research collaboration with the University of Edinburgh presents a significant growth opportunity for Neurogenesis in the field of gene therapy. The global gene therapy market is projected to reach $25 billion by 2030, driven by advances in gene editing technologies and the increasing prevalence of genetic disorders. If Neurogenesis can successfully develop and commercialize gene therapies, it could transform the company into a major player in the pharmaceutical industry. The timeline for this growth opportunity is longer-term, as gene therapy development typically involves several years of research, clinical trials, and regulatory approvals.

What Are NEUN's Competitive Advantages?

• Specialized product formulations targeting specific brain health needs.
• Research collaboration with the University of Edinburgh for gene therapy development.
• Established brand recognition in the niche market of brain health supplements.
• High gross margin indicates pricing power.

What Does NEUN Do?

Founded in 1984 and headquartered in League City, Texas, Neurogenesis, Inc. operates within the healthcare sector, specifically in the niche of specialty and generic drug manufacturing. The company develops, manufactures, and sells nutritional supplements primarily in the United States. Its product line includes NeuBecalm'd, designed to mitigate the effects of acute and chronic stress; NeuBecalm'd Chewables, aimed at reducing stress and enhancing focus; and NeuRecover, which supports the replenishment of neurotransmitters depleted by long-term alcohol use. Further expanding its offerings, Neurogenesis provides NeuReplenish for restoring brain chemistry altered by chemical stimulants, NeuRelieve to aid in rebuilding brain chemistry affected by antianxiety drugs (intended for use with professional support during tapering), and NeuSlim, which assists in managing cravings for simple carbohydrates and promoting healthy appetite control. The company also offers NeuBecalm'd/NeuRelieve Combo, a product designed to support brain chemistry restoration for individuals recovering from prescription pain pill or opiate drug use, intended to be used alongside professional guidance during the tapering process. Neurogenesis also engages in research and development, exemplified by its collaboration with the University of Edinburgh to explore gene therapy platforms. This collaboration underscores the company's commitment to innovation and its ambition to expand beyond nutritional supplements into more advanced therapeutic areas. While primarily focused on the U.S. market, Neurogenesis's research initiatives suggest potential future expansion into global markets.

What Products and Services Does NEUN Offer?

• Manufactures and sells nutritional supplements.
• Offers NeuBecalm'd to reduce the effects of stress.
• Provides NeuRecover for neurotransmitter replenishment.
• Develops NeuReplenish for restoring brain chemistry altered by chemical stimulants.
• Offers NeuRelieve to rebuild brain chemistry affected by antianxiety drugs.
• Sells NeuSlim to aid in managing cravings.
• Provides NeuBecalm'd/NeuRelieve Combo for recovery from prescription pain pill or opiate drug use.
• Collaborates with the University of Edinburgh on gene therapy development.

How Does NEUN Make Money?

• Develops and manufactures nutritional supplements.
• Sells products directly to consumers and through retailers.
• Generates revenue through product sales.
• Invests in research and development for new products and therapies.

What Industry Does NEUN Operate In?

Neurogenesis, Inc. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, evolving regulatory landscapes, and increasing demand for specialized treatments and supplements. The market for nutritional supplements, in particular, is experiencing growth driven by increasing consumer awareness of health and wellness. Neurogenesis differentiates itself by focusing on brain health and stress reduction, offering specialized products like NeuBecalm'd and NeuRecover. The company's research collaboration with the University of Edinburgh positions it to potentially enter the gene therapy market, a rapidly growing area within the pharmaceutical industry.

Who Are NEUN's Key Customers?

• Individuals seeking stress reduction.
• People looking to replenish neurotransmitters depleted by alcohol or drug use.
• Individuals aiming to restore brain chemistry altered by chemical stimulants or antianxiety drugs.
• People seeking to manage cravings for simple carbohydrates.

Company Profile

Neurogenesis, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in League City, US. The company is led by CEO Keith J. Sullivan. NEUN has traded publicly since 1998.

Return on equity for Neurogenesis, Inc. stands at -12.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.8%, showing how much profit it generates from its asset base. NEUN trades at a trailing price-to-earnings ratio of 0.53, below the Healthcare sector average of ~23x. A current ratio of 0.90 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 189.8%, the inverse of the P/E and a quick read on earnings relative to price.

NEUN Financials

NEUN Latest News

No recent news available for NEUN.

NEUN Analyst Consensus

NEUN MoonshotScore

NEUN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources